NASDAQ:CLPT ClearPoint Neuro (CLPT) Stock Price, News & Analysis → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free CLPT Stock Alerts $5.33 +0.07 (+1.33%) (As of 04/29/2024 ET) Add Compare Share Share Today's Range$5.11▼$5.4550-Day Range$5.26▼$7.8652-Week Range$4.05▼$10.57Volume153,474 shsAverage Volume110,399 shsMarket Capitalization$144.28 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ClearPoint Neuro alerts: Email Address ClearPoint Neuro MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside125.1% Upside$12.00 Price TargetShort InterestHealthy4.54% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.75) to ($0.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.83 out of 5 starsMedical Sector619th out of 920 stocksSurgical & Medical Instruments Industry69th out of 94 stocks 3.5 Analyst's Opinion Consensus RatingClearPoint Neuro has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageClearPoint Neuro has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.54% of the outstanding shares of ClearPoint Neuro have been sold short.Short Interest Ratio / Days to CoverClearPoint Neuro has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in ClearPoint Neuro has recently decreased by 3.91%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldClearPoint Neuro does not currently pay a dividend.Dividend GrowthClearPoint Neuro does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLPT. Previous Next 2.4 News and Social Media Coverage News SentimentClearPoint Neuro has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ClearPoint Neuro this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for CLPT on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows2 people have added ClearPoint Neuro to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ClearPoint Neuro insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.11% of the stock of ClearPoint Neuro is held by insiders.Percentage Held by InstitutionsOnly 30.08% of the stock of ClearPoint Neuro is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ClearPoint Neuro are expected to grow in the coming year, from ($0.75) to ($0.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ClearPoint Neuro is -5.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ClearPoint Neuro is -5.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClearPoint Neuro has a P/B Ratio of 6.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable ProsperityCharles Payne’s Gift to Stock InvestorsRight now, millions of good honest folks are feeling the squeeze. Last year's terrible market did a number on their accounts. Stock values plunged. Retirement accounts lost too.Watch Insider's Advantage Event Tuesday at 4:00 PM ET About ClearPoint Neuro Stock (NASDAQ:CLPT)ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.Read More CLPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLPT Stock News HeadlinesApril 29, 2024 | finance.yahoo.comClearPoint Neuro Announces FDA Clearance of Prism Bone Anchor AccessoryApril 24, 2024 | finance.yahoo.comClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic SystemApril 30, 2024 | Unstoppable Prosperity (Ad)Charles Payne’s Gift to Stock InvestorsRight now, millions of good honest folks are feeling the squeeze. Last year's terrible market did a number on their accounts. Stock values plunged. Retirement accounts lost too.April 23, 2024 | finance.yahoo.comClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024April 22, 2024 | markets.businessinsider.comClearPoint Neuro Poised for Growth: Strong Buy Rating Justified Amidst Market DipApril 21, 2024 | americanbankingnews.comClearPoint Neuro (NASDAQ:CLPT) vs. United American Healthcare (OTCMKTS:UAHC) Critical AnalysisApril 19, 2024 | finance.yahoo.comIs There Now An Opportunity In ClearPoint Neuro, Inc. (NASDAQ:CLPT)?April 16, 2024 | globenewswire.comClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN MutationsApril 30, 2024 | Unstoppable Prosperity (Ad)Charles Payne’s Gift to Stock InvestorsRight now, millions of good honest folks are feeling the squeeze. Last year's terrible market did a number on their accounts. Stock values plunged. Retirement accounts lost too.April 11, 2024 | investorplace.comThe 3 Most Promising MedTech Stocks to Invest In NowMarch 19, 2024 | globenewswire.comClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC DeficiencyMarch 16, 2024 | msn.comClearPoint Neuro, Inc. (NASDAQ:CLPT) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finance.yahoo.comClearPoint Neuro, Inc. (NASDAQ:CLPT) Annual Results: Here's What Analysts Are Forecasting For This YearMarch 14, 2024 | finance.yahoo.comClearPoint Neuro Full Year 2023 Earnings: Beats ExpectationsMarch 12, 2024 | finance.yahoo.comClearPoint Neuro Inc Reports Robust Revenue Growth in Q4 and Full-Year 2023March 12, 2024 | globenewswire.comClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 ResultsMarch 11, 2024 | markets.businessinsider.comClearPoint Neuro is about to announce its earnings — here's what Wall Street expectsMarch 11, 2024 | benzinga.comEarnings Outlook For ClearPoint NeuroMarch 11, 2024 | finance.yahoo.comJournal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy SystemMarch 7, 2024 | investorplace.comThe Top 7 Under-$15 Stocks to Buy in March 2024March 1, 2024 | finance.yahoo.comClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024March 1, 2024 | globenewswire.comClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024February 29, 2024 | markets.businessinsider.comClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common StockFebruary 29, 2024 | globenewswire.comClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common StockFebruary 28, 2024 | globenewswire.comClearPoint Neuro Launches Proposed Public Offering of Common StockFebruary 22, 2024 | markets.businessinsider.comClearPoint Neuro’s Strategic Growth and Regulatory Milestones Bolster Buy RatingFebruary 21, 2024 | finance.yahoo.comClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain ModelSee More Headlines Receive CLPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ClearPoint Neuro and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today4/30/2024Next Earnings (Confirmed)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:CLPT CUSIPN/A CIK1285550 Webwww.clearpointneuro.com Phone(949) 900-6833Fax949-900-6834Employees107Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$15.00 Low Stock Price Target$9.00 Potential Upside/Downside+125.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,090,000.00 Net Margins-92.21% Pretax Margin-92.21% Return on Equity-83.94% Return on Assets-47.92% Debt Debt-to-Equity Ratio0.47 Current Ratio4.87 Quick Ratio3.80 Sales & Book Value Annual Sales$23.95 million Price / Sales6.02 Cash FlowN/A Price / Cash FlowN/A Book Value$0.86 per share Price / Book6.20Miscellaneous Outstanding Shares27,070,000Free Float25,416,000Market Cap$144.28 million OptionableOptionable Beta0.89 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Joseph Michael Burnett (Age 47)President, CEO & Director Comp: $803.12kMr. Danilo D'Alessandro (Age 38)Chief Financial Officer Comp: $459.26kMr. Jeremy Stigall (Age 40)Chief Business Officer Comp: $392.66kMr. Mazin Sabra (Age 43)Chief Operating Officer Ms. Ellisa CholapraneeGeneral Counsel & SecretaryMs. Jacqueline KellerVice President of MarketingMore ExecutivesKey CompetitorsDelcath SystemsNASDAQ:DCTHOrchestra BioMedNASDAQ:OBIOQuipt Home MedicalNASDAQ:QIPTAlpha Tau MedicalNASDAQ:DRTSNeuroneticsNASDAQ:STIMView All CompetitorsInstitutional OwnershipTaylor Frigon Capital Management LLCBought 71,491 shares on 4/19/2024Ownership: 1.567%Lane Generational LLCBought 24,512 shares on 2/8/2024Ownership: 0.708%Simplex Trading LLCBought 1,600 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions CLPT Stock Analysis - Frequently Asked Questions Should I buy or sell ClearPoint Neuro stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ClearPoint Neuro in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLPT shares. View CLPT analyst ratings or view top-rated stocks. What is ClearPoint Neuro's stock price target for 2024? 3 Wall Street analysts have issued 12-month price targets for ClearPoint Neuro's shares. Their CLPT share price targets range from $9.00 to $15.00. On average, they predict the company's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 125.1% from the stock's current price. View analysts price targets for CLPT or view top-rated stocks among Wall Street analysts. How have CLPT shares performed in 2024? ClearPoint Neuro's stock was trading at $6.79 at the beginning of 2024. Since then, CLPT stock has decreased by 21.5% and is now trading at $5.33. View the best growth stocks for 2024 here. Are investors shorting ClearPoint Neuro? ClearPoint Neuro saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 1,280,000 shares, a decline of 8.6% from the March 15th total of 1,400,000 shares. Based on an average trading volume of 152,300 shares, the short-interest ratio is presently 8.4 days. View ClearPoint Neuro's Short Interest. When is ClearPoint Neuro's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our CLPT earnings forecast. How can I listen to ClearPoint Neuro's earnings call? ClearPoint Neuro will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "413671". How were ClearPoint Neuro's earnings last quarter? ClearPoint Neuro, Inc. (NASDAQ:CLPT) announced its quarterly earnings data on Tuesday, March, 12th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.03. The firm earned $6.81 million during the quarter, compared to analyst estimates of $6.40 million. ClearPoint Neuro had a negative net margin of 92.21% and a negative trailing twelve-month return on equity of 83.94%. What guidance has ClearPoint Neuro issued on next quarter's earnings? ClearPoint Neuro updated its FY 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $28.0 million-$32.0 million, compared to the consensus revenue estimate of $30.4 million. Who are ClearPoint Neuro's major shareholders? ClearPoint Neuro's stock is owned by many different institutional and retail investors. Top institutional shareholders include Taylor Frigon Capital Management LLC (1.57%). View institutional ownership trends. How do I buy shares of ClearPoint Neuro? Shares of CLPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CLPT) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingCharles Payne’s Gift to Stock InvestorsUnstoppable ProsperityHe Is Giving Away BitcoinCrypto Swap ProfitsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmith4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ClearPoint Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
